Jefferies News & Analysis
14 articles
Market Mood
BlackSky (BKSY) Stock Price Target Raised Due to Backlog Growth
Jefferies increased the stock price target for BlackSky (BKSY) following an expansion in its project backlog. The firm emphasized that the growth in backlog is a strong indicator of future revenue potential. This revision is significant as it may lead to positive market reception, influencing investor sentiment towards BKSY. Overall, the adjustment in the target could enhance trading volumes and stock performance related to BlackSky.
Read More
Apple (AAPL) Stock Target Raised Amid Strong Guidance
Jefferies raised the price target for Apple (AAPL) shares, reflecting strong guidance that was recently provided by the company. The new target is indicative of positive expectations regarding Apple's future performance and market position. This adjustment may influence investor confidence and trading volumes in AAPL. As analysts react to this revised outlook, the stock could see increased activity reflecting these anticipated gains.
Read More
eBay (EBAY) Posts 14% GMV Growth Amid Concerns for Second Half
eBay Inc (EBAY) reported a first-quarter GMV growth of 14% on an organic foreign-exchange neutral basis, driven by a 24% increase in Focus Categories. The company guided for GMV growth of up to 10% in Q2, but analysts at Jefferies noted potential deceleration due to diminishing one-time tailwinds. eBay raised its full-year 2026 GMV outlook to 7% to 7.5%, up from around 5.6%, but Jefferies expresses caution, noting a projected slowdown to just 3% GMV growth in the latter half of the year. The firm's 2026 EBITDA estimate was lowered to approximately $3.04 billion from $3.17 billion, reflecting concerns over margin growth.
Read More
Salvatore Ferragamo (SFER) Stock Initiated with Underperform Rating
Jefferies has initiated coverage on Salvatore Ferragamo (SFER) with an underperform rating. This rating suggests that analysts expect the stock to underperform compared to the market or its sector. The move comes as Salvatore Ferragamo navigates various market challenges and trends affecting luxury goods. Investors may interpret this rating as a cautionary signal regarding the company's future performance.
Read More
Boston Scientific (BSX) Price Target Cut by Jefferies on Growth Outlook
Jefferies has lowered the price target for Boston Scientific (BSX) amid concerns over its growth outlook. Specific figures on the new price target or changes in revenue estimates were not disclosed in the report. This adjustment may influence investor sentiment and trading volumes as market participants evaluate the implications for BSX. Tracking the company's performance and comparing it with sector forecasts will be essential for identifying potential market movements.
Read More
Erasca (ERAS) Stock Buy Rating Reiterated by Jefferies Ahead of ASCO
Jefferies has reiterated a Buy rating for Erasca (ERAS) stock in anticipation of upcoming data from the American Society of Clinical Oncology (ASCO) meeting. The firm supports its recommendation, suggesting confidence in future developments for ERAS. This reiteration could influence investor sentiment positively as the meeting approaches. Analysts typically use such ratings to guide purchasing decisions and assess potential market movement.
Read More
First Solar (FSLR) Price Target Cut to $187 from $205
On April 7, Jefferies analyst Julien Dumoulin-Smith reduced the price target for First Solar, Inc. (FSLR) from $205 to $187, maintaining a ‘Hold’ rating. This adjustment was driven by rising logistics costs impacting the solar energy industry due to ongoing conflicts in the Middle East. First Solar is targeting net sales between $4.9 billion and $5.2 billion for FY 2026, after a 24% revenue surge to $5.2 billion in FY 2025. Since reporting its Q4 2025 earnings on February 24, FSLR's stock has declined by over 16%, reflecting investor concerns about future revenue growth.
Read More
Alibaba (BABA) shares drop as Jefferies cuts target on spending
Shares of Alibaba (BABA) declined following a downgrade from Jefferies, which adjusted its price target amid concerns over AI spending and reported non-core losses. The rating change reflects a reevaluation of Alibaba's growth prospects as AI initiatives require significant investment, impacting profitability in the near term. Jefferies did not provide a specific target price but emphasized potential pressure on revenues due to these expenditures. This development may influence investor sentiment and market perception of BABA's valuation as they navigate financial challenges.
Read More
Twilio (TWLO) Upgrade: Jefferies Sets $160 Price Target Based on 44% Growth
Jefferies upgraded Twilio (TWLO) to Buy from Hold, with a price target of $160, reflecting a positive outlook on the company’s financials. Free cash flow for 2025 is projected at $945.4 million, representing a year-over-year increase of 44%. Furthermore, Twilio's dollar-based net expansion improved to 109%, and full-year revenue reached $5.07 billion, a 14% increase from the previous year. The upgrade comes amidst a backdrop of a declining stock price and aims to recognize Twilio's potential as an AI infrastructure provider.
Read More
Jefferies Reiterates Buy on OneSpaWorld Following Carnival Results
Jefferies has reaffirmed its Buy rating for OneSpaWorld Holdings Ltd. following the recent performance results of Carnival Corporation. Carnival's financials could influence the market perception of travel and leisure stocks, including OneSpaWorld, as they provide insights into consumer behavior and spending in the sector. The reaffirmation of the rating may suggest confidence in OneSpaWorld's growth prospects in relation to the improving cruise industry dynamics.
Read More
Jefferies Reiterates Cabaletta Bio Stock Rating Amid Product Profile Update
Jefferies has reiterated its stock rating for Cabaletta Bio. Specific details regarding the product profile were discussed, although exact figures or price targets were not provided. This reiteration may impact investor sentiment regarding the company's future prospects. Monitoring the stock's performance post-announcement could provide insights into market reactions.
Read More
Jefferies Lowers Orchestra BioMed Stock Price Target Due to Financing Costs
Jefferies has adjusted its price target for Orchestra BioMed, citing increased financing costs as a key factor. The specific new price target has not been disclosed in this article. This adjustment could impact investor sentiment towards Orchestra BioMed as it reflects concerns regarding financial sustainability. Analysts often suggest that changes in price targets can lead to volatility in stock prices.
Read More
Jefferies Maintains Pinduoduo Stock Rating Following Q4 Results
Jefferies has reaffirmed its stock rating for Pinduoduo after the company's Q4 results. The specifics of the earnings report and any changes in revenue or earnings per share (EPS) have not been disclosed in this summary. This decision reflects Jefferies' assessment of Pinduoduo's performance and expectations moving forward, indicating stability in the stock's outlook. The market reaction to this reiteration could influence investor sentiment and trading volumes.
Read More
Sumitomo Mitsui Considers Takeover Bid for Jefferies Investment Bank
Sumitomo Mitsui Financial Group's banking unit is exploring a potential takeover of Jefferies Group LLC, in which it currently holds a minority stake. This move may indicate a strategic expansion into the US investment banking sector. The specific terms and financial implications of the takeover have not been disclosed. If successful, this could significantly impact Sumitomo Mitsui's market positioning and influence the competitive landscape of investment banking.
Read More